The Fatty Liver Alliance Key Areas of Focus

---

Our Mission:

We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with nonalcoholic fatty liver disease (NAFLD), metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH) by advocating for access to approved treatments and care.

Our Vision:

To live in a country where fatty liver disease is prevented and all patients who need treatment are able to receive the best available tailored care.

Our Purpose:

To educate the public about the risks, causes, effects and complications of, and treatments for, non-alcoholic fatty liver disease through virtual and in-person presentations, conferences, meetings, and webinars, and by collecting and disseminating information on that topic. 

To promote health by conducting or funding research into the causes, controls and cure of non-alcoholic fatty liver disease and by making the results available to the public.

Our Pillars:

1. Awareness
2. Education
3. Research
4. Advocacy

An estimated 10 million people in Canada have Fatty Liver Disease, representing about 25% of the population. 

Although NAFLD (nonalcoholic fatty liver disease) could be slow to progress, when it does, it causes liver inflammation, scarring, cirrhosis, cancer and possibly death.

The Fatty Liver Alliance will focus on informing and raising awareness about this silent and potentially deadly disease.

For the Fatty Liver Alliance, education means raising the level of understanding of who is at risk, how patients can be identified through risk factors (like obesity and diabetes), which patients should be observed, and which patients should be referred to a liver specialist or other specialist (Cardiologist, Endocrinologist, Nutritionist) and finally, what treatments are currently approved and available.

As new pharmacological treatments for NASH are approved, it will be critical for those drugs to be reimbursed so that patients have access.  The Fatty Liver Alliance will always support patient care and support efforts driving access to new therapies.

We will, during this time without approved drug therapies for NASH, advocate for patients to continue with the best practices of available treatment, such as diet and exercise, and support of nutritional counsellors when required.